VEXIM: Patents Are Now Granted in Europe, US and China for MASTERFLOW®, the New High-Performance Cement Delivery System

Regulatory News:

Vexim (Paris:ALVXM) (FR0011072602 - ALVXM), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, today announces extensive IP protection of its new high performance cement delivery system MASTERFLOW®.

Thanks to unique and innovative technologies, the MASTERFLOW® allows for optimal precision, control and safety during injection of intra-vertebral cement. The cleverly designed hydraulic pump enables smooth displacement of high viscosity cement through a small diameter needle. Another essential feature of the device is the use of a zero-inertia membrane and quick-stop button arrangement, allowing the operator to instantly stop cement delivery and prevent excessive cement leakages.

As many as 18 patent applications were filed across the world to protect these innovative features. A number of those are now being granted in key European countries, the United States and China, as well as in Japan, Canada, Australia, Korea and Russia.

Vincent Gardès, CEO of VEXIM, concludes: "Our IP strategy is a cornerstone of our innovation management process. Granted patents in that many key countries are a strong demonstration of the value of the technology behind the MASTERFLOW® system. It really boosts our confidence in the future success of this new device.”

About Vexim, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital¹, and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 60 members on its staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors in Turkey, Argentina, India and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. Vexim has been listed on NYSE Alternext Paris since May 3^rd 2012.

For further information, please visit www.vexim.com

SpineJack®, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

¹ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.